

Table of contents

Chapter 1	
Introduction	7
1.1 Background	7
1.2 Drugs used in this study	17
1.3 Aim of the study	18
Chapter 2	29
Methods and materials 29	
2.1 Reagents	29
2.2 Cellular lines and primary cells cultures	29
2.3 Cell proliferation test	31
2.4 Agar clonogenic test (semisolid medium)	31
2.5 Clonogenic test of human progenitors (semisolid medium)	32
2.6 Cell cycle analysis	32
2.7 Apoptosis evaluation	33
2.8 Protein extraction and SDS page western blotting	33
2.9 Mouse models	34
2.9.1 SCID Ba/F3 JAK2 V617F –Luc+ mouse model	34
2.9.2 C57Bl6/J JAK2 V617F KI mouse model	34
2.10 Statistical methods	35
Chapter 3	
Results	39
3.1 Impairment of cell viability	39
3.2 Effect of the inhibitors on the clonogenic growth potential in agar	40
3.3 Effect of the inhibitors on cell cycle in set2 cell line	40
3.4 Effect of the inhibitors on apoptosis in set2 cell line	41
3.5 Effect of the inhibitors on protein phosphorylation	41
3.6 Effect of the inhibitors on the clonogenic potential of human primary cells	41
3.7 Effect of the inhibitors on the clonogenic potential of primary cells from murine bone marrow	43
3.8 Effect of drugs combinations on proliferation of cell lines	43
3.9 Effect of drugs combinations on clonogenic growth	43
3.10 Effect of drugs combinations on protein phosphorilation	43
3.11 Effect of drugs combinations on erithroid endogenous colonies growth inhibition	44
3.12 Combination of BEZ235 and Ruxolitinib synergistically inhibits cd34+-derived colonies from PMF patients	44

Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms

3.13. Combination treatment of BEZ235 with Ruxolitinib improves survival in mice injected with Ba/F3 cells	45
3.14. Combination treatment of BEZ235 with Ruxolitinib improves survival in knock-in mice	45
Chapter 4	
Discussion	65
References	69